Rhabdomyolysis risk from febuxostat


A combination of chronic kidney disease and statin therapy may represent a risk for the rare side-effect of rhabdomyolysis in patients treated with febuxostat for gout, a case report from St Vincent’s Hospital in Sydney suggests. Dr Debasish Ghosh and colleagues, writing in the MJA, described a 68 year old man with stage 3 CKD ...


Already a member? Login to keep reading


OR
© 2017 the limbic